United Therapeutics is pioneering a new frontier ... For example, there are patients who, outside of clinical trials, have received heart transplants from the company's gene-edited pigs.

United Therapeutics is pioneering a new frontier ... For example, there are patients who, outside of clinical trials, have received heart transplants from the company's gene-edited pigs.

A groundbreaking study in Nature Cardiovascular Research uncovers promising drug targets for heart failure (HF) and its ...

We recently compiled a list of the 10 Cheap Biotech Stocks to Invest in Now. In this article, we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR) stands against the ...

SAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 –– ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

As of 2:32:28 PM EST. Market Open. SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., February 04, 2025--United Therapeutics Corporation (Nasdaq: UTHR), a public ...